Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis

Hyun Jong Cho; Hong Yeol Yoon; Heebeom Koo; Seung Hak Ko; Jae Seong Shim; Jee Hyun Cho; Jae Hyung Park; Kwangmeyung Kim; Ick Chan Kwon; Dae Duk Kim

doi:10.1016/j.jconrel.2012.06.011

Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis

Hyun Jong Cho, Hong Yeol Yoon, Heebeom Koo, Seung Hak Ko, Jae Seong Shim, Jee Hyun Cho, Jae Hyung Park, Kwangmeyung Kim, Ick Chan Kwon, Dae Duk Kim

Department of Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Abstract

Hyaluronic acid-ceramide (HACE)-based nanoprobes for magnetic resonance (MR) and optical imaging were developed for cancer diagnosis. Diethylenetriaminepentaacetic dianhydride (DTPA) was conjugated to HACE for the chelation of gadolinium (Gd) as an MR contrast agent. Cy5.5 was also conjugated to the HACE backbone as a near-infrared fluorescence (NIRF) imaging dye. The self-assembled HACE-based nanoprobe, Cy5.5-HACE-DTPA-Gd, exhibited a uniformly distributed particle size and morphological shape. The HACE-based nanoprobe did not induce serious cytotoxicity in U87-MG (low expression of CD44 receptor) and SCC7 (high expression of CD44 receptor) cells. The cellular uptake efficiency of the HACE-based nanoprobe was higher in SCC7 cells than in U87-MG cells, indicating an HA-CD44 receptor interaction. In vitro MR signal enhancement of the HACE-based nanoprobe was confirmed compared with a commercial formulation (Magnevist). Moreover, in vivo MR contrast enhancement of the HACE-based nanoprobe in the tumor region was verified in an SCC7 tumor xenograft mouse model. The tumor targetability of the developed nanoprobe was monitored by an NIRF imaging study, and improved accumulation of the nanoprobe in the tumor region was observed. Therefore, this HACE-based dual-imaging nanoprobe can be used to make a more accurate diagnosis of cancer based on its passive and active tumor targeting strategies.

Original language	English
Pages (from-to)	111-118
Number of pages	8
Journal	Journal of Controlled Release
Volume	162
Issue number	1
DOIs	https://doi.org/10.1016/j.jconrel.2012.06.011
State	Published - 20 Aug 2012

Bibliographical note

Funding Information:
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (No. 2011‐0030635 ).

Keywords

Dual modality
Hyaluronic acid-ceramide
MRI
NIRF
Tumor targeting

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jconrel.2012.06.011

Cite this

@article{b956ad2039764250856e752e2d5387d8,

title = "Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis",

abstract = "Hyaluronic acid-ceramide (HACE)-based nanoprobes for magnetic resonance (MR) and optical imaging were developed for cancer diagnosis. Diethylenetriaminepentaacetic dianhydride (DTPA) was conjugated to HACE for the chelation of gadolinium (Gd) as an MR contrast agent. Cy5.5 was also conjugated to the HACE backbone as a near-infrared fluorescence (NIRF) imaging dye. The self-assembled HACE-based nanoprobe, Cy5.5-HACE-DTPA-Gd, exhibited a uniformly distributed particle size and morphological shape. The HACE-based nanoprobe did not induce serious cytotoxicity in U87-MG (low expression of CD44 receptor) and SCC7 (high expression of CD44 receptor) cells. The cellular uptake efficiency of the HACE-based nanoprobe was higher in SCC7 cells than in U87-MG cells, indicating an HA-CD44 receptor interaction. In vitro MR signal enhancement of the HACE-based nanoprobe was confirmed compared with a commercial formulation (Magnevist). Moreover, in vivo MR contrast enhancement of the HACE-based nanoprobe in the tumor region was verified in an SCC7 tumor xenograft mouse model. The tumor targetability of the developed nanoprobe was monitored by an NIRF imaging study, and improved accumulation of the nanoprobe in the tumor region was observed. Therefore, this HACE-based dual-imaging nanoprobe can be used to make a more accurate diagnosis of cancer based on its passive and active tumor targeting strategies.",

keywords = "Dual modality, Hyaluronic acid-ceramide, MRI, NIRF, Tumor targeting",

author = "Cho, {Hyun Jong} and Yoon, {Hong Yeol} and Heebeom Koo and Ko, {Seung Hak} and Shim, {Jae Seong} and Cho, {Jee Hyun} and Park, {Jae Hyung} and Kwangmeyung Kim and Kwon, {Ick Chan} and Kim, {Dae Duk}",

note = "Funding Information: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (No. 2011‐0030635 ). ",

year = "2012",

month = aug,

day = "20",

doi = "10.1016/j.jconrel.2012.06.011",

language = "English",

volume = "162",

pages = "111--118",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis

AU - Cho, Hyun Jong

AU - Yoon, Hong Yeol

AU - Koo, Heebeom

AU - Ko, Seung Hak

AU - Shim, Jae Seong

AU - Cho, Jee Hyun

AU - Park, Jae Hyung

AU - Kim, Kwangmeyung

AU - Kwon, Ick Chan

AU - Kim, Dae Duk

N1 - Funding Information: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (No. 2011‐0030635 ).

PY - 2012/8/20

Y1 - 2012/8/20

N2 - Hyaluronic acid-ceramide (HACE)-based nanoprobes for magnetic resonance (MR) and optical imaging were developed for cancer diagnosis. Diethylenetriaminepentaacetic dianhydride (DTPA) was conjugated to HACE for the chelation of gadolinium (Gd) as an MR contrast agent. Cy5.5 was also conjugated to the HACE backbone as a near-infrared fluorescence (NIRF) imaging dye. The self-assembled HACE-based nanoprobe, Cy5.5-HACE-DTPA-Gd, exhibited a uniformly distributed particle size and morphological shape. The HACE-based nanoprobe did not induce serious cytotoxicity in U87-MG (low expression of CD44 receptor) and SCC7 (high expression of CD44 receptor) cells. The cellular uptake efficiency of the HACE-based nanoprobe was higher in SCC7 cells than in U87-MG cells, indicating an HA-CD44 receptor interaction. In vitro MR signal enhancement of the HACE-based nanoprobe was confirmed compared with a commercial formulation (Magnevist). Moreover, in vivo MR contrast enhancement of the HACE-based nanoprobe in the tumor region was verified in an SCC7 tumor xenograft mouse model. The tumor targetability of the developed nanoprobe was monitored by an NIRF imaging study, and improved accumulation of the nanoprobe in the tumor region was observed. Therefore, this HACE-based dual-imaging nanoprobe can be used to make a more accurate diagnosis of cancer based on its passive and active tumor targeting strategies.

AB - Hyaluronic acid-ceramide (HACE)-based nanoprobes for magnetic resonance (MR) and optical imaging were developed for cancer diagnosis. Diethylenetriaminepentaacetic dianhydride (DTPA) was conjugated to HACE for the chelation of gadolinium (Gd) as an MR contrast agent. Cy5.5 was also conjugated to the HACE backbone as a near-infrared fluorescence (NIRF) imaging dye. The self-assembled HACE-based nanoprobe, Cy5.5-HACE-DTPA-Gd, exhibited a uniformly distributed particle size and morphological shape. The HACE-based nanoprobe did not induce serious cytotoxicity in U87-MG (low expression of CD44 receptor) and SCC7 (high expression of CD44 receptor) cells. The cellular uptake efficiency of the HACE-based nanoprobe was higher in SCC7 cells than in U87-MG cells, indicating an HA-CD44 receptor interaction. In vitro MR signal enhancement of the HACE-based nanoprobe was confirmed compared with a commercial formulation (Magnevist). Moreover, in vivo MR contrast enhancement of the HACE-based nanoprobe in the tumor region was verified in an SCC7 tumor xenograft mouse model. The tumor targetability of the developed nanoprobe was monitored by an NIRF imaging study, and improved accumulation of the nanoprobe in the tumor region was observed. Therefore, this HACE-based dual-imaging nanoprobe can be used to make a more accurate diagnosis of cancer based on its passive and active tumor targeting strategies.

KW - Dual modality

KW - Hyaluronic acid-ceramide

KW - MRI

KW - NIRF

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=84864663396&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2012.06.011

DO - 10.1016/j.jconrel.2012.06.011

M3 - Article

C2 - 22709587

AN - SCOPUS:84864663396

SN - 0168-3659

VL - 162

SP - 111

EP - 118

JO - Journal of Controlled Release

JF - Journal of Controlled Release

IS - 1

ER -

Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this